ResearchAntibody-Drug Conjugates in Breast Cancer: The Road Towards Biologically-Informed Selection and Sequencing
ResearchLessons From Taxanes Versus Eribulin for First-Line Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the EMERALD Study
ResearchOutcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer
ResearchImmunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8+ and PD-1+ Cells Predict Superior Patient Survival Across Major Cancer Types Independent of Major Risk Factors
ResearchGut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma, and healthy women
ResearchEvidence of accelerated epigenetic aging of breast tissues in patients with breast cancer is driven by CpGs associated with polycomb-related genes
ResearchMultidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit
ResearchTumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer
ResearchMolecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
ResearchQuantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: a case-control study
ResearchGermline variant burden in cancer genes correlates with age at diagnosis and somatic mutation burden
ResearchImmunological Differences Between Immune-Rich Estrogen Receptor-Positive and Immune-Rich Triple-Negative Breast Cancers